Cheung Sukumar MagD 2022.pdf

Objective: Poor vitamin D and magnesium status is observed in individuals who are overweight and obese (Owt/Ob) and is often associated with a heightened risk of cardiovascular disease. Magnesium is a cofactor that assists vitamin D metabolism. We aimed to determine the efficacy of a combined magnesium and vita- min D regimen compared with vitamin D only on increasing serum 25-hydroxyvitamin D (25OHD) concen- trations and the effects of these supplements on cardiometabolic outcomes.

Methods: This 12-week double-blinded randomized controlled trial had three treatment arms: magnesium + vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 £ daily), vitamin D only (VitD; 1000 IU vitamin D 3 £ daily), and placebo. A total of 95 Owt/Ob participants were randomized into one of these three study arms. Anthropometry, dietary intake, concentrations of serum 25OHD, serum parathyroid hor- mone (PTH), serum inflammatory markers, and blood pressure were obtained at baseline and week 12.

Results: The MagD group experienced the greatest increase in serum 25OHD concentrations (6.3 § 8.36 ng/ mL; P < 0.05). There was a decrease in systolic blood pressure (7.5 § 8.26 mmHg; P < 0.05) for individuals who had a baseline systolic blood pressure of >132 mmHg in the MagD group. There were no statistically sig- nificant treatment effects on serum PTH concentrations and markers of inflammation.

Conclusions: A combined MagD treatment may be more effective in increasing serum 25OHD concentrations

compared with VitD supplementation alone in Owt/Ob individuals.